Tuesday, December 11, 2012

World biotech leader Amgen invests in deCODE

I had the pleasure of meeting with Sean Harper, Amgen’s Executive Vice-President for Research and Development, and Kari Stefansson, CEO of deCODE, to learn about the acquisition of deCODE by AmGen.  I am impressed by the enormous potential this partnership will bring for the discovery of new treatments for cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. We are extraordinarily proud to see one of America’s flagship biotechnology corporations partner with a leading Icelandic firm to bring relief to patients around the world